{
    "nctId": "NCT05206331",
    "briefTitle": "CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study",
    "officialTitle": "Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 1855,
    "primaryOutcomeMeasure": "Negative Predictive Value (NPV)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject is female of any race and ethnicity\n* Subject is \u226530 years old\n* Subject is diagnosed with a suspicious breast abnormality and is scheduled for an imaging directed breast biopsy.\n\nExclusion Criteria:\n\n* Subject is unable or unwilling to undergo informed consent\n* Subject has a breast implant in the breast of interest\n* Subject is pregnant\n* Subject is breast-feeding\n* Subject is actively being treated for cancer of any type with chemotherapy\n* Subject has reduced kidney function with eGFR \\< 45.\n* Subject has had a prior reaction to iodinated contrast; thus a known allergy to iodinated contrast",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}